Embecta Revenue Drops 17.4% in Q2, Accelerates Owen Mumford Acquisition
Embecta posted a 17.4% constant currency revenue decline in Q2 2026, driven by share loss at a major U.S. customer and a shift toward lower-priced, non-preferred insulin products. The board declared a $0.01 per share dividend and the company accelerated its diversification into medical supplies via the Owen Mumford acquisition.
1. Q2 Revenue Performance
Embecta posted a 17.4% constant currency revenue decline in Q2 2026, attributed to share loss at a major U.S. customer and a patient shift toward lower-priced, non-preferred insulin products. Insulin pen prescription volumes also dipped amid rising GLP-1 therapy affordability and ACA subsidy expiration.
2. Dividend Declaration
The board declared a quarterly cash dividend of $0.01 per share, payable June 15, 2026 to shareholders of record as of May 28, 2026, reflecting the company’s commitment to return nominal cash to investors amid evolving market conditions.
3. Strategic Diversification and Acquisition
Embecta accelerated its transition from pure-play insulin delivery to a broad-based medical supplies provider with the acquisition of Owen Mumford. The company now generates 75% of revenue under the embecta label and has launched generic GLP-1 co-packaged products in India to expand its product portfolio.
4. Operational Challenges
Operational headwinds included the discontinuation of alcohol swab products due to the exit of a sole API supplier and an inability to qualify an alternative under FDA standards, highlighting the company’s supply chain vulnerabilities.